Incretin Therapy and Heart Failure
スポンサーリンク
概要
- 論文の詳細を見る
Type 2 diabetes mellitus (T2DM) is widely prevalent and a critical risk factor for cardiovascular disease that increases both morbidity and mortality. Recently, new therapies based on the actions of the incretin hormones have become widely used, offering advantages over conventional treatments by limiting hypoglycemia and achieving glycemic control. Moreover, many experimental studies have suggested that GLP-1 and related drugs exert cardioprotective effects on atherosclerosis and cardiac dysfunction both in vitro and in vivo. However, there is thus far little clinical evidence supporting the efficacy of incretin therapy in patients with cardiovascular disease. This review focuses on the effects of GLP-1-related therapy on cardiac function from the bench to the bed, with a discussion of possible underlying mechanisms.
- 一般社団法人 日本循環器学会の論文
一般社団法人 日本循環器学会 | 論文
- Evidence for Brain Activation in Patients With Takotsubo Cardiomyopathy
- Impact of Physical Activity on Cardiovascular Events in Patients With Chronic Heart Failure:– A Multicenter Prospective Cohort Study –
- Angioscopic Assessment of Peri-Stent Contrast Staining Following Drug-Eluting Stent Implantation
- Relationships of Elevated Systemic Pentraxin-3 Levels With High-Risk Coronary Plaque Components and Impaired Myocardial Perfusion After Percutaneous Coronary Intervention in Patients With ST-Elevation Acute Myocardial Infarction
- Efficacy of Percutaneous Balloon Aortic Valvuloplasty Visualized on Computed Tomography